Biolipox AB
Orexo is a commercial-stage pharmaceutical company with an international footprint, passionate about improving people's lives by offering innovative treatment solutions. Founded in Uppsala, Sweden, 30 years ago, it develops pharmaceuticals based on proprietary drug delivery technologies, with a focus on opioid dependence and other therapeutic areas. The company emphasizes sustainable outcomes, responsible business practices, and innovative drug delivery technologies like AmorphOX®. Orexo collaborates with partners for development and commercialization, and is committed to the UN Global Compact principles.
Industries
Nr. of Employees
medium (51-250)
Biolipox AB
Orexo AB, P.O. Box 303, 751 05 Uppsala, Sweden
Patents
Method of controlling depression in subjects treated for opioid dependence
US-12138259-B1
View DetailsMethod of controlling alcohol consumption in subjects treated for opioid dependence
US-11986472-B1
View Details
Method of controlling depression in subjects treated for opioid dependence
US-12138259-B1
View DetailsMethod of controlling alcohol consumption in subjects treated for opioid dependence
US-11986472-B1
View DetailsProducts
Intranasal epinephrine powder rescue product (needle-free) — clinical-stage
A powder-based intranasal epinephrine product formulated for rapid onset in emergency allergic reactions; designed for thermal stability and needle-free administration using a single-use nasal device.
Sublingual delivery-based treatments (commercialized via partners and US subsidiary)
Commercialized sublingual formulations for indications including opioid use disorder and breakthrough pain; global commercialization performed in partnership with other companies in defined regions.
Intranasal epinephrine powder rescue product (needle-free) — clinical-stage
A powder-based intranasal epinephrine product formulated for rapid onset in emergency allergic reactions; designed for thermal stability and needle-free administration using a single-use nasal device.
Sublingual delivery-based treatments (commercialized via partners and US subsidiary)
Commercialized sublingual formulations for indications including opioid use disorder and breakthrough pain; global commercialization performed in partnership with other companies in defined regions.
Services
Business development services to evaluate and apply powder-based delivery technology to external APIs, including collaborative development and commercialization discussions.
US commercialization support including market access, medical affairs, and a dedicated sales force targeting high-prevalence regions.
Development and delivery of evidence-based digital mental health programs and provider-facing online platforms to support treatment pathways.
Business development services to evaluate and apply powder-based delivery technology to external APIs, including collaborative development and commercialization discussions.
US commercialization support including market access, medical affairs, and a dedicated sales force targeting high-prevalence regions.
Development and delivery of evidence-based digital mental health programs and provider-facing online platforms to support treatment pathways.
Expertise Areas
- Powder-based drug delivery
- Intranasal delivery and needle-free rescue products
- Sublingual delivery platforms
- Formulation stability and thermal robustness
Key Technologies
- Spray-dried amorphous powder formulations
- Nasal powder delivery systems
- Single-use nasal delivery devices
- Sublingual delivery platforms